Howard L. Kaufman, MD

Howard L. Kaufman, MD, a surgical oncologist at Rutgers Cancer Institute of New Jersey, discusses a study which showed further durable responses to avelumab (Bavencio) in patients with merkel cell carcinoma who progressed after chemotherapy.

Kaufman recently coined the term "precision immunology" to describe the use of host, immune system and tumor factors as biomarkers to select immunotherapy approaches. But, are we ready to integrate precision immunology into clinical practice?

Howard L. Kaufman, MD, says that the oncology community is in its infancy in terms of selecting and sequencing immunotherapies for patients with melanoma.

Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.